Stock Price Quote

EBERS PHARMACEUTICALS LTD.

NSE : NABSE : 507715ISIN CODE : INE669D01018Industry : Pharmaceuticals & DrugsHouse : Private
BSE0.000 (0 %)
PREV CLOSE ( ) NA
OPEN PRICE ( ) 0.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 0
TODAY'S LOW / HIGH ( )0.00 0.00
52 WK LOW / HIGH ( ) 00
NSE
This Company is not listed in NSE
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1978
Management Info
- Chairman - Managing Director
Registered Office

Address 103, Shreepal Complex, Suren Road Andheri (E),
Mumbai,
Maharashtra-400093

Phone 022- 28367527 28367563

Email --

Website NA

Registrars Details
Ebers Pharmaceuticals Ltd.
103, Shreepal Complex, Suren Road Andheri (E),Mumbai
Listing : BSE

NEWS

No News Found

Financials

in Millions
QTR Mar 01 ANNUAL 01
Net Profit
Gross Profit
Operating Profit
Net Sales

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Sanofi Cons. Health (BSE)
peergroup  5024.00 (7.87%)
M.Cap ( in Cr)10681.83
Pfizer (BSE)
peergroup  5151.80 (2.62%)
M.Cap ( in Cr)22965.59
Sanofi India (BSE)
peergroup  4675.05 (1.70%)
M.Cap ( in Cr)10594.09
Alkem Laboratories (BSE)
peergroup  5837.00 (1.25%)
M.Cap ( in Cr)69200.64
Supriya Lifescience (BSE)
peergroup  817.50 (7.36%)
M.Cap ( in Cr)6153.71

Shareholding Pattern

No Data Found

About

no data found

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.